COVID-19 Impact on Global Postmenopausal Vaginal Atrophy Drugs Market Insights, Forecast to 2026
Postmenopausal Vaginal Atrophy Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Postmenopausal Vaginal Atrophy Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Postmenopausal Vaginal Atrophy Drugs market is segmented into
The Postmenopausal Vaginal Atrophy Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Postmenopausal Vaginal Atrophy Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Postmenopausal Vaginal Atrophy Drugs Market Share Analysis
Postmenopausal Vaginal Atrophy Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Postmenopausal Vaginal Atrophy Drugs business, the date to enter into the Postmenopausal Vaginal Atrophy Drugs market, Postmenopausal Vaginal Atrophy Drugs product introduction, recent developments, etc.
The major vendors covered:
Segment by Type, the Postmenopausal Vaginal Atrophy Drugs market is segmented into
- Premarin
- Vagifem
- Estrace
- Estring
- Femring
- Vaginal Gels
- Creams
- Tablets
- Rings
- Patches
The Postmenopausal Vaginal Atrophy Drugs market is analysed and market size information is provided by regions (countries).
The key regions covered in the Postmenopausal Vaginal Atrophy Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Postmenopausal Vaginal Atrophy Drugs Market Share Analysis
Postmenopausal Vaginal Atrophy Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Postmenopausal Vaginal Atrophy Drugs business, the date to enter into the Postmenopausal Vaginal Atrophy Drugs market, Postmenopausal Vaginal Atrophy Drugs product introduction, recent developments, etc.
The major vendors covered:
- Actavis plc
- Bionovo, Inc.
- Endoceutics, Inc.
- Novo Nordisk A/S
- Pfizer Inc.
- Teva Pharmaceuticals Ltd.
- Therapeutics MD, Inc.
- Shionogi & Company
- Allergan plc
- Shionogi & Co. Ltd.
1 STUDY COVERAGE
1.1 Postmenopausal Vaginal Atrophy Drugs Product Introduction
1.2 Market Segments
1.3 Key Postmenopausal Vaginal Atrophy Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type
1.4.2 Premarin
1.4.3 Vagifem
1.4.4 Estrace
1.4.5 Estring
1.4.6 Femring
1.5 Market by Application
1.5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application
1.5.2 Vaginal Gels
1.5.3 Creams
1.5.4 Tablets
1.5.5 Rings
1.5.6 Patches
1.6 Coronavirus Disease 2019 (Covid-19): Postmenopausal Vaginal Atrophy Drugs Industry Impact
1.6.1 How the Covid-19 is Affecting the Postmenopausal Vaginal Atrophy Drugs Industry
1.6.1.1 Postmenopausal Vaginal Atrophy Drugs Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Postmenopausal Vaginal Atrophy Drugs Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Postmenopausal Vaginal Atrophy Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Estimates and Forecasts
2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2015-2026
2.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2015-2026
2.2 Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2020 Versus 2026
2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS COMPETITOR LANDSCAPE BY PLAYERS
3.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
3.1.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2015-2020)
3.1.2 Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers
3.2.1 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Drugs Revenue in 2019
3.2.5 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Postmenopausal Vaginal Atrophy Drugs Price by Manufacturers
3.4 Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Product Types
3.4.1 Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type (2015-2020)
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2015-2020)
4.1.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application (2015-2020)
5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020)
5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2015-2020)
5.1.3 Postmenopausal Vaginal Atrophy Drugs Price by Application (2015-2020)
5.2 Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Postmenopausal Vaginal Atrophy Drugs by Country
6.1.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country
6.1.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
6.3 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
7 EUROPE
7.1 Europe Postmenopausal Vaginal Atrophy Drugs by Country
7.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country
7.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
7.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs by Region
8.1.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region
8.1.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
8.3 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Postmenopausal Vaginal Atrophy Drugs by Country
9.1.1 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country
9.1.2 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
9.3 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Country
10.1.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country
10.1.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 Actavis plc
11.1.1 Actavis plc Corporation Information
11.1.2 Actavis plc Description, Business Overview and Total Revenue
11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.1.5 Actavis plc Recent Development
11.2 Bionovo, Inc.
11.2.1 Bionovo, Inc. Corporation Information
11.2.2 Bionovo, Inc. Description, Business Overview and Total Revenue
11.2.3 Bionovo, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.2.5 Bionovo, Inc. Recent Development
11.3 Endoceutics, Inc.
11.3.1 Endoceutics, Inc. Corporation Information
11.3.2 Endoceutics, Inc. Description, Business Overview and Total Revenue
11.3.3 Endoceutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.3.5 Endoceutics, Inc. Recent Development
11.4 Novo Nordisk A/S
11.4.1 Novo Nordisk A/S Corporation Information
11.4.2 Novo Nordisk A/S Description, Business Overview and Total Revenue
11.4.3 Novo Nordisk A/S Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Products Offered
11.4.5 Novo Nordisk A/S Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Corporation Information
11.5.2 Pfizer Inc. Description, Business Overview and Total Revenue
11.5.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.5.5 Pfizer Inc. Recent Development
11.6 Teva Pharmaceuticals Ltd.
11.6.1 Teva Pharmaceuticals Ltd. Corporation Information
11.6.2 Teva Pharmaceuticals Ltd. Description, Business Overview and Total Revenue
11.6.3 Teva Pharmaceuticals Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.6.5 Teva Pharmaceuticals Ltd. Recent Development
11.7 Therapeutics MD, Inc.
11.7.1 Therapeutics MD, Inc. Corporation Information
11.7.2 Therapeutics MD, Inc. Description, Business Overview and Total Revenue
11.7.3 Therapeutics MD, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.7.5 Therapeutics MD, Inc. Recent Development
11.8 Shionogi & Company
11.8.1 Shionogi & Company Corporation Information
11.8.2 Shionogi & Company Description, Business Overview and Total Revenue
11.8.3 Shionogi & Company Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Products Offered
11.8.5 Shionogi & Company Recent Development
11.9 Allergan plc
11.9.1 Allergan plc Corporation Information
11.9.2 Allergan plc Description, Business Overview and Total Revenue
11.9.3 Allergan plc Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.9.5 Allergan plc Recent Development
11.10 Shionogi & Co. Ltd.
11.10.1 Shionogi & Co. Ltd. Corporation Information
11.10.2 Shionogi & Co. Ltd. Description, Business Overview and Total Revenue
11.10.3 Shionogi & Co. Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.10.5 Shionogi & Co. Ltd. Recent Development
11.1 Actavis plc
11.1.1 Actavis plc Corporation Information
11.1.2 Actavis plc Description, Business Overview and Total Revenue
11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.1.5 Actavis plc Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Region
12.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.2.2 North America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Postmenopausal Vaginal Atrophy Drugs Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Postmenopausal Vaginal Atrophy Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
1.1 Postmenopausal Vaginal Atrophy Drugs Product Introduction
1.2 Market Segments
1.3 Key Postmenopausal Vaginal Atrophy Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type
1.4.2 Premarin
1.4.3 Vagifem
1.4.4 Estrace
1.4.5 Estring
1.4.6 Femring
1.5 Market by Application
1.5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application
1.5.2 Vaginal Gels
1.5.3 Creams
1.5.4 Tablets
1.5.5 Rings
1.5.6 Patches
1.6 Coronavirus Disease 2019 (Covid-19): Postmenopausal Vaginal Atrophy Drugs Industry Impact
1.6.1 How the Covid-19 is Affecting the Postmenopausal Vaginal Atrophy Drugs Industry
1.6.1.1 Postmenopausal Vaginal Atrophy Drugs Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Postmenopausal Vaginal Atrophy Drugs Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Postmenopausal Vaginal Atrophy Drugs Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 EXECUTIVE SUMMARY
2.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size Estimates and Forecasts
2.1.1 Global Postmenopausal Vaginal Atrophy Drugs Revenue 2015-2026
2.1.2 Global Postmenopausal Vaginal Atrophy Drugs Sales 2015-2026
2.2 Postmenopausal Vaginal Atrophy Drugs Market Size by Region: 2020 Versus 2026
2.2.1 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Postmenopausal Vaginal Atrophy Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 GLOBAL POSTMENOPAUSAL VAGINAL ATROPHY DRUGS COMPETITOR LANDSCAPE BY PLAYERS
3.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers
3.1.1 Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2015-2020)
3.1.2 Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers
3.2.1 Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Postmenopausal Vaginal Atrophy Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Postmenopausal Vaginal Atrophy Drugs Revenue in 2019
3.2.5 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Postmenopausal Vaginal Atrophy Drugs Price by Manufacturers
3.4 Postmenopausal Vaginal Atrophy Drugs Manufacturing Base Distribution, Product Types
3.4.1 Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Type (2015-2020)
4.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020)
4.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2015-2020)
4.1.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Postmenopausal Vaginal Atrophy Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Postmenopausal Vaginal Atrophy Drugs Market Size by Application (2015-2020)
5.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020)
5.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue by Application (2015-2020)
5.1.3 Postmenopausal Vaginal Atrophy Drugs Price by Application (2015-2020)
5.2 Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Postmenopausal Vaginal Atrophy Drugs Price Forecast by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Postmenopausal Vaginal Atrophy Drugs by Country
6.1.1 North America Postmenopausal Vaginal Atrophy Drugs Sales by Country
6.1.2 North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
6.3 North America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
7 EUROPE
7.1 Europe Postmenopausal Vaginal Atrophy Drugs by Country
7.1.1 Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country
7.1.2 Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
7.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
8 ASIA PACIFIC
8.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs by Region
8.1.1 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region
8.1.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
8.3 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
9 LATIN AMERICA
9.1 Latin America Postmenopausal Vaginal Atrophy Drugs by Country
9.1.1 Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country
9.1.2 Latin America Postmenopausal Vaginal Atrophy Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
9.3 Central & South America Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
10 MIDDLE EAST AND AFRICA
10.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs by Country
10.1.1 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country
10.1.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Facts & Figures by Application
11 COMPANY PROFILES
11.1 Actavis plc
11.1.1 Actavis plc Corporation Information
11.1.2 Actavis plc Description, Business Overview and Total Revenue
11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.1.5 Actavis plc Recent Development
11.2 Bionovo, Inc.
11.2.1 Bionovo, Inc. Corporation Information
11.2.2 Bionovo, Inc. Description, Business Overview and Total Revenue
11.2.3 Bionovo, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.2.5 Bionovo, Inc. Recent Development
11.3 Endoceutics, Inc.
11.3.1 Endoceutics, Inc. Corporation Information
11.3.2 Endoceutics, Inc. Description, Business Overview and Total Revenue
11.3.3 Endoceutics, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.3.5 Endoceutics, Inc. Recent Development
11.4 Novo Nordisk A/S
11.4.1 Novo Nordisk A/S Corporation Information
11.4.2 Novo Nordisk A/S Description, Business Overview and Total Revenue
11.4.3 Novo Nordisk A/S Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Products Offered
11.4.5 Novo Nordisk A/S Recent Development
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Corporation Information
11.5.2 Pfizer Inc. Description, Business Overview and Total Revenue
11.5.3 Pfizer Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.5.5 Pfizer Inc. Recent Development
11.6 Teva Pharmaceuticals Ltd.
11.6.1 Teva Pharmaceuticals Ltd. Corporation Information
11.6.2 Teva Pharmaceuticals Ltd. Description, Business Overview and Total Revenue
11.6.3 Teva Pharmaceuticals Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.6.5 Teva Pharmaceuticals Ltd. Recent Development
11.7 Therapeutics MD, Inc.
11.7.1 Therapeutics MD, Inc. Corporation Information
11.7.2 Therapeutics MD, Inc. Description, Business Overview and Total Revenue
11.7.3 Therapeutics MD, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.7.5 Therapeutics MD, Inc. Recent Development
11.8 Shionogi & Company
11.8.1 Shionogi & Company Corporation Information
11.8.2 Shionogi & Company Description, Business Overview and Total Revenue
11.8.3 Shionogi & Company Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Products Offered
11.8.5 Shionogi & Company Recent Development
11.9 Allergan plc
11.9.1 Allergan plc Corporation Information
11.9.2 Allergan plc Description, Business Overview and Total Revenue
11.9.3 Allergan plc Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Allergan plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.9.5 Allergan plc Recent Development
11.10 Shionogi & Co. Ltd.
11.10.1 Shionogi & Co. Ltd. Corporation Information
11.10.2 Shionogi & Co. Ltd. Description, Business Overview and Total Revenue
11.10.3 Shionogi & Co. Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Products Offered
11.10.5 Shionogi & Co. Ltd. Recent Development
11.1 Actavis plc
11.1.1 Actavis plc Corporation Information
11.1.2 Actavis plc Description, Business Overview and Total Revenue
11.1.3 Actavis plc Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Actavis plc Postmenopausal Vaginal Atrophy Drugs Products Offered
11.1.5 Actavis plc Recent Development
12 FUTURE FORECAST BY REGIONS (COUNTRIES) (2021-2026)
12.1 Postmenopausal Vaginal Atrophy Drugs Market Estimates and Projections by Region
12.1.1 Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.2.2 North America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Market Size Forecast by Country (2021-2026)
13 MARKET OPPORTUNITIES, CHALLENGES, RISKS AND INFLUENCES FACTORS ANALYSIS
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Postmenopausal Vaginal Atrophy Drugs Players (Opinion Leaders)
14 VALUE CHAIN AND SALES CHANNELS ANALYSIS
14.1 Value Chain Analysis
14.2 Postmenopausal Vaginal Atrophy Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
LIST OF TABLES
Table 1. Postmenopausal Vaginal Atrophy Drugs Market Segments
Table 2. Ranking of Global Top Postmenopausal Vaginal Atrophy Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Premarin
Table 5. Major Manufacturers of Vagifem
Table 6. Major Manufacturers of Estrace
Table 7. Major Manufacturers of Estring
Table 8. Major Manufacturers of Femring
Table 9. COVID-19 Impact Global Market: (Four Postmenopausal Vaginal Atrophy Drugs Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Postmenopausal Vaginal Atrophy Drugs Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Postmenopausal Vaginal Atrophy Drugs Players to Combat Covid-19 Impact
Table 14. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 15. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 16. Global Postmenopausal Vaginal Atrophy Drugs Sales by Regions 2015-2020 (K Units)
Table 17. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Regions (2015-2020)
Table 18. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 19. Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturers (2015-2020)
Table 21. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 22. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2019)
Table 23. Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 24. Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2015-2020)
Table 25. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Price (2015-2020) (USD/Unit)
Table 26. Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 27. Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 28. Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2015-2020)
Table 32. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2015-2020) (US$ Million)
Table 33. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2015-2020)
Table 34. Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 35. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 36. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2015-2020)
Table 37. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 38. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 39. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 40. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 41. North America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 42. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 43. North America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 44. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 45. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 46. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 47. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 48. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 49. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 50. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 51. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 52. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 53. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2015-2020) (K Units)
Table 54. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2015-2020)
Table 55. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2015-2020) (US$ Million)
Table 56. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2015-2020)
Table 57. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 58. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 59. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 60. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 61. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 62. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 63. Latin Americaa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 64. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 65. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 66. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 67. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 68. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 69. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 70. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 71. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 72. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 73. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 74. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 75. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 76. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 77. Actavis plc Corporation Information
Table 78. Actavis plc Description and Major Businesses
Table 79. Actavis plc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Actavis plc Product
Table 81. Actavis plc Recent Development
Table 82. Bionovo, Inc. Corporation Information
Table 83. Bionovo, Inc. Description and Major Businesses
Table 84. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Bionovo, Inc. Product
Table 86. Bionovo, Inc. Recent Development
Table 87. Endoceutics, Inc. Corporation Information
Table 88. Endoceutics, Inc. Description and Major Businesses
Table 89. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Endoceutics, Inc. Product
Table 91. Endoceutics, Inc. Recent Development
Table 92. Novo Nordisk A/S Corporation Information
Table 93. Novo Nordisk A/S Description and Major Businesses
Table 94. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Novo Nordisk A/S Product
Table 96. Novo Nordisk A/S Recent Development
Table 97. Pfizer Inc. Corporation Information
Table 98. Pfizer Inc. Description and Major Businesses
Table 99. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Pfizer Inc. Product
Table 101. Pfizer Inc. Recent Development
Table 102. Teva Pharmaceuticals Ltd. Corporation Information
Table 103. Teva Pharmaceuticals Ltd. Description and Major Businesses
Table 104. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. Teva Pharmaceuticals Ltd. Product
Table 106. Teva Pharmaceuticals Ltd. Recent Development
Table 107. Therapeutics MD, Inc. Corporation Information
Table 108. Therapeutics MD, Inc. Description and Major Businesses
Table 109. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 110. Therapeutics MD, Inc. Product
Table 111. Therapeutics MD, Inc. Recent Development
Table 112. Shionogi & Company Corporation Information
Table 113. Shionogi & Company Description and Major Businesses
Table 114. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 115. Shionogi & Company Product
Table 116. Shionogi & Company Recent Development
Table 117. Allergan plc Corporation Information
Table 118. Allergan plc Description and Major Businesses
Table 119. Allergan plc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 120. Allergan plc Product
Table 121. Allergan plc Recent Development
Table 122. Shionogi & Co. Ltd. Corporation Information
Table 123. Shionogi & Co. Ltd. Description and Major Businesses
Table 124. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 125. Shionogi & Co. Ltd. Product
Table 126. Shionogi & Co. Ltd. Recent Development
Table 127. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 128. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 129. Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 130. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 131. North America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 132. North America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 133. Europe: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 134. Europe: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 135. Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 136. Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 137. Latin America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 138. Latin America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 139. Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 140. Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 141. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 142. Key Challenges
Table 143. Market Risks
Table 144. Main Points Interviewed from Key Postmenopausal Vaginal Atrophy Drugs Players
Table 145. Postmenopausal Vaginal Atrophy Drugs Customers List
Table 146. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
Table 1. Postmenopausal Vaginal Atrophy Drugs Market Segments
Table 2. Ranking of Global Top Postmenopausal Vaginal Atrophy Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Premarin
Table 5. Major Manufacturers of Vagifem
Table 6. Major Manufacturers of Estrace
Table 7. Major Manufacturers of Estring
Table 8. Major Manufacturers of Femring
Table 9. COVID-19 Impact Global Market: (Four Postmenopausal Vaginal Atrophy Drugs Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Postmenopausal Vaginal Atrophy Drugs Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Postmenopausal Vaginal Atrophy Drugs Players to Combat Covid-19 Impact
Table 14. Global Postmenopausal Vaginal Atrophy Drugs Market Size Growth Rate by Application 2020-2026 (K Units)
Table 15. Global Postmenopausal Vaginal Atrophy Drugs Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 16. Global Postmenopausal Vaginal Atrophy Drugs Sales by Regions 2015-2020 (K Units)
Table 17. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Regions (2015-2020)
Table 18. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 19. Global Postmenopausal Vaginal Atrophy Drugs Sales by Manufacturers (2015-2020) (K Units)
Table 20. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturers (2015-2020)
Table 21. Global Postmenopausal Vaginal Atrophy Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 22. Global Postmenopausal Vaginal Atrophy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Postmenopausal Vaginal Atrophy Drugs as of 2019)
Table 23. Postmenopausal Vaginal Atrophy Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 24. Postmenopausal Vaginal Atrophy Drugs Revenue Share by Manufacturers (2015-2020)
Table 25. Key Manufacturers Postmenopausal Vaginal Atrophy Drugs Price (2015-2020) (USD/Unit)
Table 26. Postmenopausal Vaginal Atrophy Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 27. Manufacturers Postmenopausal Vaginal Atrophy Drugs Product Type
Table 28. Date of International Manufacturers Enter into Postmenopausal Vaginal Atrophy Drugs Market
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. Global Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Type (2015-2020)
Table 32. Global Postmenopausal Vaginal Atrophy Drugs Revenue by Type (2015-2020) (US$ Million)
Table 33. Global Postmenopausal Vaginal Atrophy Drugs Revenue Share by Type (2015-2020)
Table 34. Postmenopausal Vaginal Atrophy Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 35. Global Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 36. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Application (2015-2020)
Table 37. North America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 38. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 39. North America Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 40. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 41. North America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 42. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 43. North America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 44. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 45. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 46. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 47. Europe Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 48. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 49. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 50. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 51. Europe Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 52. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 53. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Region (2015-2020) (K Units)
Table 54. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2015-2020)
Table 55. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue by Region (2015-2020) (US$ Million)
Table 56. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2015-2020)
Table 57. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 58. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 59. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 60. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 61. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 62. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 63. Latin Americaa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 64. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 65. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 66. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 67. Latin America Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 68. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 69. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Country (2015-2020) (K Units)
Table 70. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country (2015-2020)
Table 71. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue by Country (2015-2020) (US$ Million)
Table 72. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country (2015-2020)
Table 73. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Type (2015-2020) (K Units)
Table 74. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Table 75. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales by Application (2015-2020) (K Units)
Table 76. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Table 77. Actavis plc Corporation Information
Table 78. Actavis plc Description and Major Businesses
Table 79. Actavis plc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 80. Actavis plc Product
Table 81. Actavis plc Recent Development
Table 82. Bionovo, Inc. Corporation Information
Table 83. Bionovo, Inc. Description and Major Businesses
Table 84. Bionovo, Inc. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 85. Bionovo, Inc. Product
Table 86. Bionovo, Inc. Recent Development
Table 87. Endoceutics, Inc. Corporation Information
Table 88. Endoceutics, Inc. Description and Major Businesses
Table 89. Endoceutics, Inc. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 90. Endoceutics, Inc. Product
Table 91. Endoceutics, Inc. Recent Development
Table 92. Novo Nordisk A/S Corporation Information
Table 93. Novo Nordisk A/S Description and Major Businesses
Table 94. Novo Nordisk A/S Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 95. Novo Nordisk A/S Product
Table 96. Novo Nordisk A/S Recent Development
Table 97. Pfizer Inc. Corporation Information
Table 98. Pfizer Inc. Description and Major Businesses
Table 99. Pfizer Inc. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 100. Pfizer Inc. Product
Table 101. Pfizer Inc. Recent Development
Table 102. Teva Pharmaceuticals Ltd. Corporation Information
Table 103. Teva Pharmaceuticals Ltd. Description and Major Businesses
Table 104. Teva Pharmaceuticals Ltd. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 105. Teva Pharmaceuticals Ltd. Product
Table 106. Teva Pharmaceuticals Ltd. Recent Development
Table 107. Therapeutics MD, Inc. Corporation Information
Table 108. Therapeutics MD, Inc. Description and Major Businesses
Table 109. Therapeutics MD, Inc. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 110. Therapeutics MD, Inc. Product
Table 111. Therapeutics MD, Inc. Recent Development
Table 112. Shionogi & Company Corporation Information
Table 113. Shionogi & Company Description and Major Businesses
Table 114. Shionogi & Company Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 115. Shionogi & Company Product
Table 116. Shionogi & Company Recent Development
Table 117. Allergan plc Corporation Information
Table 118. Allergan plc Description and Major Businesses
Table 119. Allergan plc Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 120. Allergan plc Product
Table 121. Allergan plc Recent Development
Table 122. Shionogi & Co. Ltd. Corporation Information
Table 123. Shionogi & Co. Ltd. Description and Major Businesses
Table 124. Shionogi & Co. Ltd. Postmenopausal Vaginal Atrophy Drugs Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 125. Shionogi & Co. Ltd. Product
Table 126. Shionogi & Co. Ltd. Recent Development
Table 127. Global Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Regions (2021-2026) (K Units)
Table 128. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 129. Global Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 130. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 131. North America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 132. North America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 133. Europe: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 134. Europe: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 135. Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Region (2021-2026) (K Units)
Table 136. Asia Pacific: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 137. Latin America: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 138. Latin America: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 139. Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Sales Forecast by Country (2021-2026) (K Units)
Table 140. Middle East and Africa: Postmenopausal Vaginal Atrophy Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 141. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 142. Key Challenges
Table 143. Market Risks
Table 144. Main Points Interviewed from Key Postmenopausal Vaginal Atrophy Drugs Players
Table 145. Postmenopausal Vaginal Atrophy Drugs Customers List
Table 146. Postmenopausal Vaginal Atrophy Drugs Distributors List
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Postmenopausal Vaginal Atrophy Drugs Product Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Premarin Product Picture
Figure 4. Vagifem Product Picture
Figure 5. Estrace Product Picture
Figure 6. Estring Product Picture
Figure 7. Femring Product Picture
Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2020 & 2026
Figure 9. Vaginal Gels
Figure 10. Creams
Figure 11. Tablets
Figure 12. Rings
Figure 13. Patches
Figure 14. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Market Size 2015-2026 (US$ Million)
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Sales 2015-2026 (K Units)
Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2015-2020)
Figure 19. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region in 2019
Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2015-2020)
Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region in 2019
Figure 22. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturer in 2019
Figure 23. The Top 10 and 5 Players Market Share by Postmenopausal Vaginal Atrophy Drugs Revenue in 2019
Figure 24. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 25. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Figure 26. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2019
Figure 27. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2015-2020)
Figure 28. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type in 2019
Figure 29. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Price Range (2015-2020)
Figure 30. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Figure 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2019
Figure 32. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2015-2020)
Figure 33. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application in 2019
Figure 34. North America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 35. North America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 36. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2019
Figure 37. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2019
Figure 38. U.S. Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 39. U.S. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. Canada Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 41. Canada Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. North America Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2019
Figure 43. North America Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2019
Figure 44. Europe Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 45. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 46. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2019
Figure 47. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2019
Figure 48. Germany Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 49. Germany Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. France Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 51. France Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. U.K. Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 53. U.K. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Italy Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 55. Italy Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Russia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 57. Russia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Europe Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2019
Figure 59. Europe Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2019
Figure 60. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 61. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 62. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region in 2019
Figure 63. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region in 2019
Figure 64. China Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 65. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Japan Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 67. Japan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. South Korea Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 69. South Korea Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. India Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 71. India Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Australia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 73. Australia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Taiwan Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 75. Taiwan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Indonesia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 77. Indonesia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Thailand Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 79. Thailand Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Malaysia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 81. Malaysia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Philippines Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 83. Philippines Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Vietnam Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 85. Vietnam Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2019
Figure 87. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2019
Figure 88. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 89. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 90. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2019
Figure 91. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2019
Figure 92. Mexico Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 93. Mexico Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Brazil Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 95. Brazil Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Argentina Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 97. Argentina Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Latin America Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2019
Figure 99. Latin America Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2019
Figure 100. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 101. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 102. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2019
Figure 103. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2019
Figure 104. Turkey Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 105. Turkey Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 107. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. U.A.E Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 109. U.A.E Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2019
Figure 111. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2019
Figure 112. Actavis plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Bionovo, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Endoceutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Novo Nordisk A/S Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Pfizer Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. Teva Pharmaceuticals Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. Therapeutics MD, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. Shionogi & Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 120. Allergan plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 121. Shionogi & Co. Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 122. North America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 123. North America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Europe Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 125. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 126. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 127. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 128. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 129. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 130. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 131. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 132. Porter's Five Forces Analysis
Figure 133. Channels of Distribution
Figure 134. Distributors Profiles
Figure 135. Bottom-up and Top-down Approaches for This Report
Figure 136. Data Triangulation
Figure 137. Key Executives Interviewed
Figure 1. Postmenopausal Vaginal Atrophy Drugs Product Picture
Figure 2. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Premarin Product Picture
Figure 4. Vagifem Product Picture
Figure 5. Estrace Product Picture
Figure 6. Estring Product Picture
Figure 7. Femring Product Picture
Figure 8. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2020 & 2026
Figure 9. Vaginal Gels
Figure 10. Creams
Figure 11. Tablets
Figure 12. Rings
Figure 13. Patches
Figure 14. Postmenopausal Vaginal Atrophy Drugs Report Years Considered
Figure 15. Global Postmenopausal Vaginal Atrophy Drugs Market Size 2015-2026 (US$ Million)
Figure 16. Global Postmenopausal Vaginal Atrophy Drugs Sales 2015-2026 (K Units)
Figure 17. Global Postmenopausal Vaginal Atrophy Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 18. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region (2015-2020)
Figure 19. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region in 2019
Figure 20. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region (2015-2020)
Figure 21. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region in 2019
Figure 22. Global Postmenopausal Vaginal Atrophy Drugs Sales Share by Manufacturer in 2019
Figure 23. The Top 10 and 5 Players Market Share by Postmenopausal Vaginal Atrophy Drugs Revenue in 2019
Figure 24. Postmenopausal Vaginal Atrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 25. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type (2015-2020)
Figure 26. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Type in 2019
Figure 27. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type (2015-2020)
Figure 28. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Type in 2019
Figure 29. Global Postmenopausal Vaginal Atrophy Drugs Market Share by Price Range (2015-2020)
Figure 30. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application (2015-2020)
Figure 31. Global Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Application in 2019
Figure 32. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application (2015-2020)
Figure 33. Global Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Application in 2019
Figure 34. North America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 35. North America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 36. North America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2019
Figure 37. North America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2019
Figure 38. U.S. Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 39. U.S. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 40. Canada Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 41. Canada Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 42. North America Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2019
Figure 43. North America Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2019
Figure 44. Europe Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 45. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 46. Europe Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2019
Figure 47. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2019
Figure 48. Germany Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 49. Germany Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 50. France Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 51. France Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 52. U.K. Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 53. U.K. Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 54. Italy Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 55. Italy Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 56. Russia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 57. Russia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 58. Europe Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2019
Figure 59. Europe Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2019
Figure 60. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 61. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 62. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Region in 2019
Figure 63. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Region in 2019
Figure 64. China Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 65. China Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 66. Japan Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 67. Japan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 68. South Korea Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 69. South Korea Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 70. India Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 71. India Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 72. Australia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 73. Australia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 74. Taiwan Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 75. Taiwan Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 76. Indonesia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 77. Indonesia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 78. Thailand Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 79. Thailand Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 80. Malaysia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 81. Malaysia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 82. Philippines Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 83. Philippines Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 84. Vietnam Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 85. Vietnam Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 86. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2019
Figure 87. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2019
Figure 88. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 89. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 90. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2019
Figure 91. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2019
Figure 92. Mexico Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 93. Mexico Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 94. Brazil Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 95. Brazil Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 96. Argentina Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 97. Argentina Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 98. Latin America Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2019
Figure 99. Latin America Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2019
Figure 100. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate 2015-2020 (K Units)
Figure 101. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 102. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Market Share by Country in 2019
Figure 103. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Market Share by Country in 2019
Figure 104. Turkey Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 105. Turkey Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 106. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 107. Saudi Arabia Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 108. U.A.E Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate (2015-2020) (K Units)
Figure 109. U.A.E Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate (2015-2020) (US$ Million)
Figure 110. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Share by Type in 2019
Figure 111. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Market Share by Application in 2019
Figure 112. Actavis plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 113. Bionovo, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 114. Endoceutics, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 115. Novo Nordisk A/S Total Revenue (US$ Million): 2019 Compared with 2018
Figure 116. Pfizer Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 117. Teva Pharmaceuticals Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 118. Therapeutics MD, Inc. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 119. Shionogi & Company Total Revenue (US$ Million): 2019 Compared with 2018
Figure 120. Allergan plc Total Revenue (US$ Million): 2019 Compared with 2018
Figure 121. Shionogi & Co. Ltd. Total Revenue (US$ Million): 2019 Compared with 2018
Figure 122. North America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 123. North America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 124. Europe Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 125. Europe Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 126. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 127. Asia Pacific Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 128. Latin America Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 129. Latin America Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 130. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 131. Middle East and Africa Postmenopausal Vaginal Atrophy Drugs Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 132. Porter's Five Forces Analysis
Figure 133. Channels of Distribution
Figure 134. Distributors Profiles
Figure 135. Bottom-up and Top-down Approaches for This Report
Figure 136. Data Triangulation
Figure 137. Key Executives Interviewed
